Gerald J. Maarman, Stellenbosch University
Pulmonary hypertension is elevated blood pressure that occurs exclusively in the lungs. It is a deadly condition that affects an estimated 75 million people worldwide. Around 80% of them live in low- and middle-income countries. In a recent literature review my colleagues and I found that the prevalence of pulmonary hypertension in Africa can range anything from 10% to 68%.
Pulmonary hypertension is completely different from systemic hypertension, a disease many people develop between the ages of 55-70. With pulmonary hypertension, cells in the blood vessels of the lung become cancerous as they continue to multiply or grow uncontrollably. This makes the vessels narrower than normal, leading to high blood pressure in the lung. The difference between these two conditions means that conventional hypertension medications are not effective against pulmonary hypertension – a misconception among some primary healthcare doctors.
It’s not understood why certain patients develop it and others not. Pulmonary hypertension is considered to be a medical consequence of several other conditions. These include left heart disease, HIV infection, tuberculosis (TB), bilharzia or schistosomiasis, and chronic obstructive pulmonary disease such as asthma, emphysema and chronic bronchitis. Patients with any of these diseases are at risk of developing pulmonary hypertension.
In South Africa, the risk of pulmonary hypertension is increased because of high levels of HIV, TB, and chronic obstructive pulmonary disease. Even if patients are cured from TB, some will later die of pulmonary hypertension. Many people with HIV are also at risk of developing pulmonary hypertension and dying from it. Thousands of people are at risk of dying from pulmonary hypertension considering the high prevalence of TB and HIV on the continent.
To complicate this even further, pulmonary hypertension is not easily picked up by primary healthcare doctors due to the unspecific nature of the symptoms. This could lead to the misconception that the patient might have a persistent cold or flu, to only later – when it is too late – find out that it was pulmonary hypertension.
With statistics suggesting that thousands of people might die from this disease, something has to be done. Advocacy could potentially increase awareness for, and clinical interest in pulmonary hypertension. This is especially important among clinicians and researchers in the primary, secondary, and tertiary healthcare sectors.
Raising awareness could lead to the much-needed shift in thinking similar to what has driven established pulmonary hypertension centres around the world.
Challenges
Symptoms of pulmonary hypertension include shortness of breath, inability to do simple physical activities such as picking up items from the floor or walking up stairs. Other symptoms can be chest pain and a persistent cough. These symptoms are not specific for pulmonary hypertension, and this means that the condition is often misdiagnosed or confused with other diseases, leading to a delayed diagnosis.
Delayed diagnosis of pulmonary hypertension has long been recognised as a significant challenge in low- and middle-income countries where there are limited resources. Patients could be seen by a primary healthcare physician for months or years and still not get the appropriate diagnosis. This delay is sadly fatal because even specialised treatments are ineffective at a progressed stage of the disease. The number of people suffering from pulmonary hypertension without getting a proper diagnosis or better treatment is unknown.
There’s a lack of awareness in the primary healthcare sector and gross under-diagnosis due to a lack of resources. The disease may be more prevalent than is frequently described in the literature.
Many doctors are also overwhelmed with the burden of infectious diseases in low- and middle-income countries. These working conditions can draw attention away from detecting pulmonary hypertension at an early stage.
The gold standard for diagnosing pulmonary hypertension is right heart catheterisation. But this is an invasive technique, during which a catheter is inserted into the right side of the heart through an incision made in the neck of the patient. This procedure is not always conducted in less fortunate countries, and less accessible in remote areas where patients are far from a cardiologist with experience in right heart catheterisation.
In the past, patients with pulmonary hypertension have died within three to five years of diagnosis. But with advancements in drug development, this has changed, and the use of different combinations of specialised drugs can increase patient survival for up to nine years.
But there’s a challenge. Many of these specialised drugs are expensive and not available in low- and middle-income countries. Sadly, a lot of patients with pulmonary hypertension die as a result. This further highlights a global need for better treatment options. These options must be affordable and accessible to patients from low- and middle-income countries.
Opportunities
There is an opportunity to research, define and investigate factors that cause pulmonary hypertension in low- and middle-income countries. Here, the unique causes of pulmonary hypertension – uncommon in developed countries – are more prevalent.
In areas where access to investigations is limited, pragmatic and potentially non-invasive diagnostic and treatment methods could be adopted. This may lower the barriers to treatment. It is important that doctors adjust diagnostic protocols to determine an earlier diagnosis, especially in the context of low- and middle-income countries. This has led to the observation that a cheaper, non-invasive technique, heart scan (similar to an ultrasound scan done on pregnant women), is sufficient to confirm pulmonary hypertension in patients of countries where right heart catheterization is not possible.
An overview of the total number of pulmonary hypertension cases – newly diagnoses and existing – is important. This can be achieved by the use of national data registries and by doing frequent review of national patient-databases.
Gerald J. Maarman, Lecturer & Principal Investigator, CARMA: Centre for Cardio-Metabolic Research in Africa, Stellenbosch University
This article is republished from The Conversation under a Creative Commons license. Read the original article.
